Overview

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The study design of this trial is double blind, parallel-group, randomized, placebo controlled study
Phase:
Phase 3
Details
Lead Sponsor:
Handok Inc.
Handok Pharmaceuticals Co., Ltd.
Treatments:
Dipeptidyl-Peptidase IV Inhibitors